Blood Transfusions

Sangart awarded patent for blood substitute product

Published in Blood Weekly, October 10th, 2002

Sangart, Inc., a biopharmaceutical company developing oxygen transport agents, announced that it received a notice of allowance from the United States Patent and Trademark Office for the patent application entitled "Methods and compositions for optimization of oxygen transport by cell-free systems."

The new patent, which is part of a family of several U.S. patents that were previously issued, significantly expands the scope of protection available to Sangart's products including its lead oxygen transport agent, Hemospan. The entire family of patents is licensed to Sangart on an exclusive world-wide basis.

"This patent further strengthens our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry